U.S. Markets closed
  • S&P Futures

    4,064.75
    -10.75 (-0.26%)
     
  • Dow Futures

    33,999.00
    -24.00 (-0.07%)
     
  • Nasdaq Futures

    12,043.00
    -63.75 (-0.53%)
     
  • Russell 2000 Futures

    1,906.80
    -3.70 (-0.19%)
     
  • Crude Oil

    81.22
    +0.21 (+0.26%)
     
  • Gold

    1,928.30
    -1.70 (-0.09%)
     
  • Silver

    23.96
    -0.06 (-0.25%)
     
  • EUR/USD

    1.0889
    -0.0004 (-0.0327%)
     
  • 10-Yr Bond

    3.4930
    +0.0310 (+0.90%)
     
  • Vix

    18.73
    -0.35 (-1.83%)
     
  • GBP/USD

    1.2405
    -0.0002 (-0.0186%)
     
  • USD/JPY

    129.6920
    -0.4610 (-0.3542%)
     
  • BTC-USD

    22,789.42
    -399.45 (-1.72%)
     
  • CMC Crypto 200

    516.49
    -10.69 (-2.03%)
     
  • FTSE 100

    7,761.11
    +16.24 (+0.21%)
     
  • Nikkei 225

    27,377.91
    +15.16 (+0.06%)
     

Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease

  • Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has appointed Jeffrey M. Goldberg as president, chief executive officer, and a board member, effective November 29, 2022.

  • Jim Kastenmayer will step down as interim chief executive officer and retain his position as Aeglea's general counsel.

  • Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 trial of pegtarviliase in Classical Homocystinuria in the fourth quarter of 2022.

  • Enrollment in the third cohort of the Phase 1/2 trial is ongoing, with two patients having completed dosing in the cohort.

  • In October, the FDA placed a partial clinical hold for enrolling patients under 18 years of age under the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria Investigational New Drug (IND).

  • Additionally, the company has decided not to participate in the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.

  • Aeglea looks forward to delivering a clinical update on the pegtarviliase program when more comprehensive data from the third cohort becomes available.

  • Price Action: AGLE shares are down 58.9% at $0.5010 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.